HUTCHMED (China) Limited ADR (HCM)

Schlusskurs vom Vortag:

$19.45

Offen:

$19.2

24-Stunden-Volumen:

76,857

Marktkapitalisierung:

$3.32B

Einnahmen:

$838.00M

Nettoeinkommen (Verlust:

$100.78M

KGV:

-77.88

EPS:

-0.25

Netto-Cashflow:

$186.65M

1W Leistung:

+3.78%

1M Leistung:

+15.41%

6M Leistung:

-0.15%

1J Leistung:

+25.45%

1-Tages-Spanne:

$19.19

$19.51

52-Wochen-Spanne:

$10.68

$20.73

HUTCHMED (China) Limited ADR Stock (HCM) Company Profile

Firmenname

HUTCHMED (China) Limited ADR

Sektor

Healthcare (1217)

Branche

Drug Manufacturers - Specialty & Generic (3)

Telefon

852 2121 8200

Adresse

Hutchison House, 22nd Floor 10 Harcourt Road, Central

Mitarbeiter

590

Twitter

@hchimed

Nächster Verdiensttermin

2024-06-05

Neueste SEC-Einreichungen

HCM's Discussions on Twitter

HUTCHMED (China) Limited ADR Stock (HCM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-24	Hochstufung	Deutsche Bank	Hold → Buy
2022-05-04	Herabstufung	Deutsche Bank	Buy → Hold
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-08-03	Eingeleitet	Jefferies	Buy
2020-10-02	Eingeleitet	Deutsche Bank	Buy
2020-03-13	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-20	Eingeleitet	Goldman	Buy
2019-11-19	Eingeleitet	CLSA	Buy
2019-10-23	Bestätigt	BofA/Merrill	Buy
2019-07-05	Eingeleitet	Macquarie	Outperform

Alle ansehen

HUTCHMED (China) Limited ADR Aktie (HCM) Neueste Nachrichten

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire Inc.

HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?

Zacks Investment Research

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

GlobeNewswire Inc.

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

GlobeNewswire Inc.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

GlobeNewswire Inc.

Finanzdaten der HUTCHMED (China) Limited ADR-Aktie (HCM)

HUTCHMED (China) Limited ADR (HCM) Umsatz 2024

HUTCHMED (China) Limited ADR (HCM) Nettogewinn 2024

HUTCHMED (China) Limited ADR (HCM) Free Cashflow 2024

HUTCHMED (China) Limited ADR (HCM) Gewinn je Aktie 2024